NCT04873570View on ClinicalTrials.gov

Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

May 28, 2021

Primary Completion Date

June 8, 2021

Study Completion Date

June 10, 2021

Conditions
Healthy IndividualsBioequivalence Study
Interventions
DRUG

Moxifloxacin 400mg

Moxifloxacin 400mg IR tablet

Trial Locations (1)

75270

Center for Bioequivalence Studies and clinical research, Karachi

All Listed Sponsors
collaborator

SAMI Pharmaceutical, Karachi Pakistan

UNKNOWN

collaborator

Center for Bioequivalence Studies and Clinical Research

OTHER

lead

University of Karachi

OTHER

NCT04873570 - Bioequivalence Study of Mofest® 400mg (Moxifloxacin) Tablet With Avelox® 400mg (Moxifloxacin) Tablet in Healthy Pakistani Subjects | Biotech Hunter | Biotech Hunter